Dokumendiregister | Ravimiamet |
Viit | REP-1/3193-2 |
Registreeritud | 26.06.2025 |
Sünkroonitud | 27.06.2025 |
Liik | Väljaminev kiri |
Funktsioon | REP Euroopa Farmakopöaga seotud asjaajamine |
Sari | REP-1 Euroopa Farmakopöa alane kirjavahetus |
Toimik | REP-1/2025 |
Juurdepääsupiirang | Avalik |
Juurdepääsupiirang | |
Adressaat | European Directorate for the Quality of Medicines & HealthCare |
Saabumis/saatmisviis | European Directorate for the Quality of Medicines & HealthCare |
Vastutaja | Signe Leito (RA, Peadirektori asetäitja valdkond, Labor) |
Originaal | Ava uues aknas |
Proposed suppression of the monograph on Pivampicillin (0852) from the Ph. Eur.
page 1 / 4
Q1-4 (4257)
NPA: (54023) Type: (!/list-dropdown)
A10 - Estonia (EE)
Please choose: (54024) Type: (L/list-radio)
In favour of the suppression of the monograph on Pivampicillin (0852) from the European Pharmacopoeia
A1
page 2 / 4
If your answer is "opposed", could you please justify your reply and/or provide details of
marketing authorisations of medicines containing substance covered by this monograph that
may exist in your country?
(54025) Type: (T/text-long)
-
Can you approve the accompanying note outlining the reasons for suppression as reproduced
here below? This note will be published on Knowledge Database :
This monograph is published in Pharmeuropa to inform all stakeholders that the text is proposed for suppression from the Ph. Eur.
Any stakeholders wishing either to share any important information or concerns directly related to this suppression process are requested to submit a detailed comment.
Pivampicillin is a semi-synthetic antibiotic derived from ampicillin and belonging to the class of penicillins.
The monograph on Pivampicillin (0852) was published in the Ph. Eur. in 1993 for the first time.
Since that date, the related substances method was not revised, although experience has shown
that it lacked specificity. Moreover, the test in question contains only a limit of maximum 3 per
cent for the total of impurities; no impurity is specified, which is not in accordance with current
guidelines. Therefore, this monograph would require a complete revision.
page 3 / 4
However, no drug product containing pivampicillin and no manufacturers of the drug substance could be identified on the European market.
It is therefore proposed to suppress the monograph on Pivampicillin (0852) from the European
Pharmacopoeia.
(54027) Type: (L/list-radio)
Yes
A1
Remarks: (54026) Type: (T/text-long)
No medicinal products containing pivampicillin are authorised, and no manufacturers of pivampicillin are approved in Estonia.
Powered by TCPDF (www.tcpdf.org)
page 4 / 4
Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
---|---|---|---|---|---|---|
Euroopa farmakopöaga seoses | 26.06.2025 | 1 | REP-1/3193-1 | Sissetulev kiri | ra | European Directorate for the Quality of Medicines & HealthCare |